Search | All Crowdz

Atharva Patil added blog Health
2026-04-07 09:31:32 -

Radiopharmaceutical Theranostics Market Poised for Robust Growth as Precision Medicine Advances
The global Radiopharmaceutical Theranostics Market is on a robust growth trajectory, driven by the paradigm shift towards personalized medicine, the increasing incidence of cancer worldwide, and continuous technological advancements in nuclear medicine. According to a comprehensive report by Market Research Future, the market was valued at USD 2.11 billion in 2024. It is projected to...

0 Comments 0 Shares 283 Views 0 Reviews

Please log in to like, share and comment!
Anuj Mrfr added blog Health
2026-05-01 08:35:20 -

Radiopharmaceutical Theranostics Market: How Are Major Companies Competing in the Commercial Landscape?
Radiopharmaceutical theranostics competitive landscape — the Novartis/AAA dominance, Lantheus Holdings, POINT Biopharma (Eli Lilly), RayzeBio (Bristol-Myers Squibb), Fusion Pharmaceuticals (AstraZeneca), and dozens of pipeline companies creating the commercial ecosystem, with the Radiopharmaceutical Theranostics Market reflecting competitive dynamics as an increasingly active commercial...

0 Comments 0 Shares 143 Views 0 Reviews

Please log in to like, share and comment!
Anuj Mrfr added blog Health
2026-04-14 11:13:34 -

Radiopharmaceutical Theranostics Market: How Is Lutetium-177 PSMA Therapy Transforming Prostate Cancer?
Lutetium-177 PSMA radioligand therapy — the targeted radionuclide treatment delivering beta-emitting Lu-177 directly to prostate-specific membrane antigen-expressing prostate cancer cells — represents the most commercially significant radiopharmaceutical theranostics launch in the market's history, with the Radiopharmaceutical Theranostics Market reflecting Lu-177 PSMA as the...

0 Comments 0 Shares 202 Views 0 Reviews

Please log in to like, share and comment!
Anuj Mrfr added blog Health
2026-02-13 06:47:52 -

The "Neurological" Horizon: How 2026 is Using "Hot" Molecules to Treat Alzheimer's.
In late 2026, the industry is pivoting toward "Neuro-Theranostics." While oncology remains the anchor, a radical new class of "Amyloid-Clearing Radiopharmaceuticals" has entered Phase 2 trials, aiming to use targeted radiation to break down the plaques associated with Alzheimer's disease. This innovation is a primary driver for the market, as it promises to treat the brain with...

0 Comments 0 Shares 491 Views 0 Reviews

Please log in to like, share and comment!